Biochemical and Immunogenetic Diagnostic Markers Less Commonly Used for Predicting the Efficacy of Chronic Hepatitis C Etiotropic Therapy

Abstract

Introduction: 1,7% of the population of Latvia in 2008 was HCV RNA positive, thus approximately 38 thousands required the CHC antiviral therapy. The objective of the study was to evaluate some biochemical and immunogenetic parameters allowing predicting the efficacy of the etiotropic therapy for CHC patients. Material and methods: Medical records of 213 CHC patients were analyzed. HCV RNA, anti-HCV, concentration of HA, GGT activity were detected and immunogenetic investigations were performed. Results and discussion: Evaluation of GGT activity showed increase in 46,81% of non-responders and in only 21,57% responders. HA level in responders was significantly lower than in non-responders. Correlation between the incidence of HLA class II gene alleles in CHC patients and the type of CHC therapy was found. The results of the study confirmed the hypothesis that some biochemical and immunogenetic parameters characterizing the condition of the macro organism had an essential role in the efficacy of the CHC therapy. Conclusions: The non-efficacy of the CHC etiotropic therapy was associated with increased GGT and HA levels upon the start of the therapy. The efficacy of PEG IFN+RBV combination therapy in comparison with the efficacy of Realdiron therapy was associated with different MHC HLA class II gene alleles.